Dapagliflozin: do its benefits extend to the critically ill?
DEFENDER trial goes on a statistical deep dive to not find out
Dapagliflozin is the sodium-glucose cotransporter 2 (SGLT-2) inhibitor sold as Farxiga™ by AstraZeneca and Bristol Myers-Squibb. SGLT-2 inhibitors improve diabetes by causing the kidney to excrete excess glucose, which led to their FDA-approved indication for diabetes management.
These remarkable compounds somehow also improve outcomes in heart failure …
Keep reading with a 7-day free trial
Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.